Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Bone Health Observational Study (BHOS)

The recruitment status of this study is unknown because the information has not been verified recently.
Verified May 2011 by CMX Research.
Recruitment status was  Active, not recruiting
Sponsor:
Collaborator:
AstraZeneca
Information provided by:
CMX Research
ClinicalTrials.gov Identifier:
NCT00632905
First received: February 20, 2008
Last updated: May 30, 2011
Last verified: May 2011

February 20, 2008
May 30, 2011
September 2007
Not Provided
Bone Mineral Density of the lumbar spine [ Time Frame: 12 months ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT00632905 on ClinicalTrials.gov Archive Site
Overall Safety [ Time Frame: 12 Months ] [ Designated as safety issue: Yes ]
Same as current
Not Provided
Not Provided
 
Bone Health Observational Study
A Prospective Study to Evaluate the Incidence of Skeletal Related Events In Prostate Cancer Patients Undergoing Androgen Deprivation Therapy (ADT).

Prostate Cancer patients treated with LHRH agonists (e.g., goserelin) lose Bone Mineral Density (BMD). Using a prospective, observational study design, we propose that monitoring how physicians manage Cancer Treatment Induced Bone Loss(CTIBL) in their patients. The gold standard for evaluating BMD is dual energy x-ray absorptiometry (DEXA). The proposed study will provide some of the first prospective data on the rates of Skeletal Related Events (SREs) in prostate cancer patients undergoing ADT and help develop official guidelines on the use of DEXA screening for prostate cancer patients.

A consequence of ADT is the gradual bone loss, so-called cancer treatment induced bone loss (CTIBL). The current standard of care is the addition of Vitamin D and Calcium upon the initiation of ADT. Moreover, bisphosphonates are now being considered to treat and prevent CTIBL. However, bisphosphonates are costly, thus there is a desire to identify or target a specific subset of patients who would most benefit from the treatment.

By obtaining baseline BMD and monitoring for Skeletal Related Events (SREs), we hope to identify that specific sub-set of patients who would most benefit from the treatment. Using a prospective, observational study design, we propose monitoring how physicians manage CTIBL in their patients.

Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample

primary care clinics

Prostate Cancer
Not Provided
  • 1
    Normal - BMD with T-score at or above -1.0
  • 2
    Osteopenic - BMD with T-score between -1.1 and -2.4
  • 3
    Osteoporotic - BMD with T-score at or below -2.5
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
300
Not Provided
Not Provided

Inclusion Criteria:

  • Patients willing to provide written Informed Consent.
  • Patients for whom Androgen Deprivation Therapy (ADT) with Zoladex® is indicated for at least 1 year.
  • Patients started on Zoladex® within the last 4 months.

Exclusion Criteria:

  • Patient had surgery or significant traumatic injury occurring within 1 month prior to consent.
  • Known hypersensitivity to Goserelin Acetate or any of the components found in Zoladex®.
  • Any concurrent condition that would make it undesirable, in the physician's opinion, for the subject to participate in the study or would jeopardize compliance with the protocol.
Male
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Canada
 
NCT00632905
AZ-CMX-03
No
Aaron Park/Project Manager, CMX Research
CMX Research
AstraZeneca
Principal Investigator: Richard W Casey, M.D. CMX Research
CMX Research
May 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP